Loading...
01/11 03:07
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The company has raised its full-year revenue guidance and EPS, indicating strong financial performance. Despite some management ambiguity on future metrics, the overall sentiment is positive with strategic growth plans, including Artegraft and XenoSure expansion, and a robust sales force strategy. The market cap suggests moderate reaction, predicting a 2-8% stock price increase.
Organic Sales Growth 12% year-over-year growth. Reasons: Higher pricing (10%) and unit growth (2%).
Gross Margin Reported gross margin was 75.3%, adjusted gross margin was 70.8%, a 300 basis point year-over-year increase. Reasons: Higher pricing, manufacturing efficiencies, and product mix.
Operating Income Reported operating income was $20.3 million, adjusted operating income was $16.9 million, up 29% year-over-year. Reasons: Gross margin improvements and operating expense control.
Operating Margin Reported operating margin was 33%, adjusted operating margin was 28%, up from 21% in Q1 and 25% in Q2. Reasons: Operating leverage from gross margin improvements and expense control.
Net Income Reported net income was $17.4 million, adjusted net income was $14.2 million, up 27% year-over-year. Reasons: Gross margin improvements and operating expense control.
Diluted EPS Reported diluted EPS was $0.75, adjusted diluted EPS was $0.62, up 27% year-over-year. Reasons: Gross margin improvements and operating expense control.
Revenue Growth Year-over-year reported revenue growth was 11%. Reasons: Reduced by $1.3 million due to Aziyo distribution exit, benefited by $1 million from weaker U.S. dollar.
Cash and Securities Ended the quarter with $343.1 million, an increase of $23.6 million. Reasons: Generated $28.8 million in cash from operations, paid $4.5 million in dividends.
Adjusted Operating Expenses $26.3 million, an increase of 9% year-over-year. Reasons: Higher compensation expenses and European investments in Ireland, Switzerland, Czechia, and Portugal.
Artegraft: International launch exceeded expectations with Q2 sales of $420,000, Q3 sales of $1.4 million, and expected Q4 sales of $2 million. Artegraft grew 33% worldwide in Q3. Approvals in Canada and Korea expected in 2026.
RestoreFlow: Received German approval in October, with distribution anticipated in Q2 2026. Irish approval expected in H1 2026, which should accelerate other EU approvals.
European Market Expansion: Leased a European RFA distribution facility in Dublin to support launches. Distributed $2.7 million of tissues in the U.K. over the last 12 months.
Price Adjustments: Published 2026 U.S. hospital price list with an 8% increase. 55% of North American revenue now subject to price floors. International price lists are being finalized.
Sales Force Adjustments: Ended Q3 with 152 reps after reducing 8 sales reps based on performance. 23 open rep hiring requisitions with a target of 165 reps by year-end.
New Distribution Center: Opening a 34,000 square foot distribution center near Burlington headquarters in Q1 2026.
Operational Leverage: Achieved adjusted operating margin improvements over the first three quarters of 2025 (21%, 25%, 28%) and guiding 29% in Q4.
FDA Warning Letter: New Jersey Artegraft facility received an FDA warning letter related to quality management system. Written responses provided, and operations remain unaffected.
FDA Warning Letter: The New Jersey Artegraft facility received an FDA warning letter related to the quality management system. While it has not disrupted production, shipping, or invoicing, it represents a regulatory risk that could impact operations if not resolved.
April Recall Impact: The recall led to some customers front-loading catheter purchases into Q2, reducing Q3 organic and unit growth. This indicates potential disruptions in sales patterns and customer purchasing behavior.
Aziyo Distribution Exit: Year-over-year reported revenue growth was reduced by $1.3 million due to the exit from Aziyo distribution, highlighting a challenge in maintaining revenue streams.
European Investments and Expenses: Higher compensation expenses and investments in Ireland, Switzerland, Czechia, and Portugal drove increased operating expenses in H1, which could pressure margins if not offset by revenue growth.
Currency Exchange Impact: The weaker U.S. dollar added $1 million to reported sales, but currency fluctuations remain a risk to financial performance.
Artegraft Sales: Q4 2025 sales expected to reach $2 million. Artegraft approvals anticipated in Canada and Korea in 2026.
RestoreFlow Distribution: German approval received in October 2025; distribution to begin in Q2 2026. Irish approval expected in H1 2026, which should accelerate other EU approvals.
European Market Expansion: Leased a European RFA distribution facility in Dublin to support launches. Distributed $2.7 million of tissues in the U.K. over the last 12 months.
Sales Force Expansion: Currently 23 open rep hiring requisitions; expect to have 165 reps by year-end 2025.
2026 U.S. Price List: Published with an 8% increase; 55% of North American revenue now subject to price floors.
New Distribution Center: Opening a 34,000 square foot facility near Burlington headquarters in Q1 2026.
Q4 2025 Operating Income Growth: Guiding 40% operating income growth with a 29% operating margin.
2025 Full Year Revenue Guidance: $248 million, representing 13% growth.
2025 Full Year Adjusted Gross Margin: Expected to be 70.3%.
2025 Full Year Adjusted Operating Income: Guidance of $63.7 million, up 22%, resulting in a 26% adjusted operating margin.
2025 Full Year Adjusted EPS: Guidance of $2.37, an increase of 22% over 2024.
Dividends paid in Q3 2025: $4.5 million in dividends were paid to shareholders.
The company has raised its full-year revenue guidance and EPS, indicating strong financial performance. Despite some management ambiguity on future metrics, the overall sentiment is positive with strategic growth plans, including Artegraft and XenoSure expansion, and a robust sales force strategy. The market cap suggests moderate reaction, predicting a 2-8% stock price increase.
The earnings call reflects a positive outlook with increased sales guidance, strong international growth, and optimistic product feedback. Despite minor setbacks, such as not reaching the sales rep target and uncertainty in price hikes, the overall sentiment is bolstered by strategic international expansions and improved margins. The market cap suggests a moderate reaction, aligning with a 'Positive' sentiment.
The earnings call indicates strong financial performance with a 12% increase in Q1 sales, improved gross margins, and an increase in organic sales growth guidance from 10% to 13%. Despite some concerns in the Q&A about Xenosure in China and vague responses regarding share buybacks, the overall sentiment is positive due to the increased guidance and strategic moves like exiting the declining Elutia distribution. The market cap suggests moderate volatility, leading to a positive stock price prediction (2% to 8%) over the next two weeks.
The earnings call indicates strong financial performance with significant sales and EPS growth, a 25% dividend increase, and improved margins. While there are potential challenges in new markets and supply chain complexities, the guidance remains optimistic, expecting 10% organic growth. The Q&A section reveals management's cautious optimism and strategic hiring plans, although some answers were vague. Given the company's market cap, the positive financial metrics and shareholder returns suggest a likely positive stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
